One in Nine Adults Take a GLP-1 for Weight Loss. Here Is Why Most Plans Still Won't Pay
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
About one in nine US adults now takes a GLP-1 for weight loss (Gallup). The drugs work, but more than half of the people using them say they're hard to afford (KFF). And 2027 could make that harder, because employers, insurers and Medicare are each deciding whether to keep paying for them.
This post walks through why that's happening, what changed in 2026, and what you can do now to prepare for next year.
Who This Helps
This is for anyone paying full price for a GLP-1 and wondering why a drug that's supposed to save money in the long term through reduced healthcare costs isn't covered. It's also for anyone whose plan just dropped coverage, and for anyone comparing self-pay options for next year.
Why don't plans count the long-term savings?
GLP-1s are expected to lower health costs over time, as people avoid problems like diabetes and heart disease. The trouble is timing. Those savings tend to show up years later, while the drug bill arrives every month and has to be paid now.
You can see that tension in the research. The benefits firm Aon looked at claims from more than 50 million people. It found that by the 30-month mark, medical costs were growing 6% more slowly for people with diabetes who took a GLP-1 than for those who didn't (Healthcare Dive). That's a long wait for a plan that sets its budget one year at a time.
The federal budget office has looked at the same question for Medicare. In 2024, it estimated that covering obesity drugs would cost about $35 billion more than it saved through 2034, though it called that estimate highly uncertain (CBO). That estimate came before Medicare negotiated a lower price for these drugs, so the gap today may be smaller.
Why are employers pulling back?
Employers are the biggest source of coverage in the US, and many of them are rethinking it. Part of the reason is that people change jobs. The typical worker has been with their current employer about four years (BLS). That means a company that pays for the drug today may not be the one that benefits when its workers are healthier years from now.
The newest surveys show coverage holding flat or slipping. KFF found that 18% of companies with 200 or more workers cover GLP-1s for weight loss, about the same as last year, but coverage at the very largest companies fell from 43% to 33% (KFF). A separate survey from the consulting firm WTW found that 30% of employers that still cover the drugs are thinking about dropping them, almost all because of cost (Becker's).
Employers that keep coverage are often adding conditions. About 40% of them now ask workers to join a lifestyle program or work with a dietitian or case manager while they take the drug, up from about a third last year (KFF).
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
What about Medicare?
By law, Medicare can't cover drugs used only for weight loss, and that's been true since its drug benefit started (KFF). It does cover GLP-1s for diabetes, heart risk and sleep apnea.
In July 2026, Medicare opened a temporary program called the Medicare GLP-1 Bridge. If you qualify, you pay $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, with prior authorization. It's set to end in 2027, though. KFF warns that people who start the drug through the Bridge could "lose access in 2028." A longer-term Medicare plan for obesity drugs that was supposed to begin in January 2027 has been delayed with no new date (KFF).
There's also a Medicare price change coming. On January 1, 2027, Medicare's negotiated price for semaglutide, the drug in Ozempic, Rybelsus and Wegovy, drops to $274 for a month's supply (CMS). That applies to covered uses like diabetes, not weight loss on its own.
Some states are paying, and others have stopped
State employee health plans show how differently payers are deciding. Illinois has covered GLP-1s for weight loss for its state workers since July 2024 (Becker's Payer). A state spokesperson said the goal is that "more people will have a chance to eliminate long-term health problems" (WBEZ).
Massachusetts went the other way. In February 2026, the board that runs its state employee plan voted to end coverage for weight loss after spending $46 million on it (WBUR). North Carolina's plan had already stopped covering the drugs for weight loss after its monthly spending climbed from about $3 million to more than $14 million (WRAL).
What could bring prices down?
Lower prices could change the picture, and some are already here. If you pay out of pocket, the drugmakers' own self-pay prices are well below list price, which means they could be lower than an insurance copay for some. As of early November, NovoCare lists Wegovy at $349 a month (NovoCare), and LillyDirect lists Zepbound KwikPens starting at $299 for the lowest dose (LillyDirect). These offers change often, so check the company pages before you count on a number.
List prices are starting to fall too. Novo Nordisk plans to cut the list price of Wegovy and Ozempic to $675 a month in January 2027 (Yahoo Finance). This will help most if you're on a high-deductible plan, where what you pay often follows the list price.
Generic versions are further off. The FDA gave a generic semaglutide injection tentative approval in April 2026, but it can't be sold until patents and other protections run out (HCPLive). Compounded GLP-1s, which some people use today, are made to order by pharmacies and aren't the same thing as an approved generic.
How to prepare for 2027
If your plan covers a GLP-1 now, find out whether it will next year before open enrollment closes. Our guide to checking a plan for GLP-1 coverage walks you through what to look for.
If you're on Medicare, ask your prescriber about the Bridge soon, since it needs prior authorization and is set to end after 2027. And if your employer has dropped coverage, ask HR whether it offers anything in its place. KFF notes that employers can help pay for drugmakers' direct-to-consumer programs through account contributions, even when the health plan itself doesn't cover the drug (KFF).
Final Takeaway
About one in nine US adults takes a GLP-1 for weight loss, and more than half of them say the drugs are hard to afford. Employers are holding steady or cutting back, Medicare's $50 program runs only through 2027, and states are split. The savings these drugs may bring tend to arrive years after the bills, which is a big part of why so many plans hesitate. For now, the most useful numbers to watch are the drugmakers' self-pay prices and your own plan's coverage for 2027.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Why won't my insurance cover my GLP-1 for weight loss?
Usually because of cost. Plans pay for the drug every month, while the health savings tend to show up years later, and many employers are holding coverage flat or cutting it in 2026. Medicare is barred by law from covering drugs used only for weight loss, though a temporary program runs through 2027.
Does Medicare cover Wegovy or Zepbound for weight loss?
Not under the usual rules. The temporary Medicare GLP-1 Bridge lets people who qualify pay $50 a month for Wegovy, Foundayo or the Zepbound KwikPen through December 2027, with prior authorization. The $50 doesn't count toward your Part D deductible or out-of-pocket cap.
When will generic Ozempic or Wegovy be available?
Not soon. A generic semaglutide injection has tentative FDA approval, but it can't be sold until patents and other protections expire. Compounded semaglutide is made by pharmacies and isn't an approved generic.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
What Medicare, insurance, and federal policy signals really mean for GLP-1 coverage in 2026, including access rules, costs, and eligibility.
Learn what’s changing in 2026 insurance plans for GLP-1 drugs and how to compare costs, coverage, and plan options to stay protected.
Prescription approved but insurance said no? Learn your next options for Wegovy, Ozempic, or Zepbound coverage and care.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.